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The pleotropic nature of TNFa has been well docu-New Haven, CT 06510
mented in nonobese diabetic (NOD)mice, which sponta-
neously develop autoimmune diabetes, a chronic T cell±
mediated disease that is characterized by lymphocyticSummary
infiltration of the pancreatic islets (insulitis) and by the
selective destruction of insulin-producing b cells (TischRecent experiments have suggested that tumor ne-
and McDevitt, 1996). Experiments demonstrating thatcrosis factor a (TNFa) can down-regulate islet-specific
TNFa mRNA is produced in situ in inflamed islets in NODT cells and prevent the development of autoimmune
mice have suggested that TNFa plays a pivotal role indiabetes. Here we demonstrate that transgenic mice
the disease process (Held et al., 1990). Consistent withexpressing bothTNFa and the Leishmania majorLACK
this hypothesis, treatment of newborn NOD mice withantigen in the pancreas (RIP-TNFa/RIP-LACK) exhibit
recombinant TNFa or with neutralizing anti-TNFa mono-an impaired ability to mount a CD41 T cell response
clonal antibodies (MAbs) or soluble TNF receptor leadsagainst LACK. In addition, peripheralCD41 T cells from
to earlier onset or complete prevention of disease, re-
TCR transgenic mice (TCR-LACK/RIP-TNFa/RIP-
spectively (Yang et al., 1994; Hunger et al., 1997).
LACK) produced reduced interleukin-2 but elevated
TNFa may be directly involved in the destruction of b
levels of T helper 2 cytokines in response to LACK cells themselves or may contribute to the diabetogenic
peptide in vitro. Taken together, our data suggest that process through the recruitment of autoreactive T cells
TNFa may act in vivo to modulate a potentially damag- to the inflamed islets. The generation of transgenic mice
ing self-reactive T cell response by inducing tolerance
that express TNFa in pancreatic b cells (RIP-TNFa mice)
to pancreatic antigens. has demonstrated that at least the latter may be true,
since these mice develop increasingly massive lympho-
Introduction cytic infiltration within the islets, apparently resulting
from the induction of endothelial changes (Higuchi et
Tumor necrosis factor a (TNFa) is a potent inflammatory al., 1992; Picarella et al., 1993). However, recruitment of
mediator that is involved in the pathological processes a cellular infiltrate is not sufficient for the induction of
found in a number of autoimmune and infectious disease the disease, since RIP-TNFa transgenic mice do not
states (Ruddle et al., 1990; Jacob, 1992; Lane et al., become diabetic, even after perfusion with other cyto-
1992; Vassalli, 1992). TNFa is produced predominantly kines, mild damaging of b cells, or transgenic expression
by activated macrophages, but also by other cell types of a viral antigen on b cells (Higuchi, et al., 1992). More-
such as mast cells, neutrophils, and CD41 T helper 1 over, RIP-TNFa mice generated on the NOD background
(Th1) cells (Vassalli, 1992). The ubiquitous expression do not progress from insulitis to diabetes, suggesting
of TNF receptors suggests that TNFa may mediate a that TNFa may actually inhibit one of the late phases of
number of biological activities in a wide variety of cells the disease process (Grewal et al., 1996). Indeed, these
data are in agreement with earlier studies that demon-
strated that TNFa, when administered to NOD mice after# To whom correspondence should be addressed.
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4 weeks of age, can dramatically prevent the onset of
the disease (Satoh et al., 1989; Jacob et al., 1990). It is
not known how spontaneous or experimentally induced
local expression of TNFa in islets could prevent or delay
the development of diabetes. However, this protective
effect of transgenic TNFa production in NOD mice was
found to correlate with a lack of T cell responsiveness
to islet antigens, a process that occurs spontaneously
in NOD mice.
To elucidate how local expression of TNFa can affect
T cell responses directed to islet antigens, we generated
double-transgenic mice by crossing RIP-TNFa mice (Pi-
carella et al., 1993) to transgenic mice in which the ex-
pression of the L. major LACK antigen (Mougneau et al.,
1995) was restricted to pancreatic b cells. We found
that these mice failed to mount a T cell response to
LACK after immunization and also developed depressed
LACK-specific antibody responses when compared to Figure 1. Expression of LACK mRNA Is Restricted to Pancreatic
single-transgenic RIP-LACK mice or negative litter- Islets in RIP-LACK Transgenic Mice
mates. This phenomenon was analyzed further by breed- The presence of LACK-specific mRNA was examined in transgenic
ing these mice with TCR-LACK transgenic mice that ex- (1/2) and nontransgenic (2/2) mice by amplifying cDNA made from
the indicated tissues using LACK-specific primers.press a TCR transgene specific for a class II±restricted
LACK peptide. Taken together, our data suggest that
local expression of TNFa can lead to the development
nontransgenic littermates (Figures 2A and 2B). Evenof tolerance to pancreatic antigens, which may account
though RIP-LACK mice were not tolerant to LACK, theyfor the previously reported capacity of this cytokine to
did not develop diabetes, either spontaneously or fol-prevent the development of autoimmune disease.
lowing infection with L. major or immunization with LACK
in CFA (data not shown).
Results
To determine how the transgenic expression of TNFa
in islet b cells would affect immune responses to a de-
Generation of Transgenic Mice Expressing fined pancreatic antigen, we crossed RIP-LACK to RIP-
the L. major LACK Antigen TNFa transgenic mice. Surprisingly, when these mice
in Pancreatic b Cells were immunized with LACK, lymph node T cells from
To determine how the local expression of TNFa would double-transgenic mice produced less IFNg and IL-5 in
affect T cell responses to pancreatic antigens, we bred
response to LACK in vitro than cells from RIP-TNFa or
RIP-TNFa mice to another transgenic strain in which the
RIP-LACK single-transgenic mice, indicating that these
expression of the L. major cytoplasmic LACK antigen
mice were tolerant to LACK (Figures 2A and 2B). These
was directed to the b cells (RIP-LACK). RIP-LACK found-
results were confirmed when we directly measured the
ers were crossed to BALB/c mice, and offspring were
numbers of IL-5± and IFNg-secreting cells in thedraining
monitored for LACK expression using reverse transcrip-
lymph nodes of immunized mice using a sensitive ELIS-
tion polymerase chain reaction (RT-PCR). The expres-
POT assay (Figures 3A and 3C). The number of IL-4±
sion of LACK mRNA was detected in purified pancreatic
secreting cells was also reduced in double-transgenic
islets but not in any other organs examined, including RIP-LACK/RIP-TNFa mice as compared to that in mice
thymus, liver, spleen, and kidneys (Figure 1). One RIP- from the other three groups (Figure 3B). In agreement
LACK founder was backcrossed to BALB/c mice for five with these results, reduced amounts of LACK-specific
generations, and the colony was subsequently ex- immunoglobulin G1 (IgG1) and IgG2a were found in
panded. RIP-LACK mice were monitored for more than the serum of immunized RIP-LACK/RIP-TNFa double-
1 year by measurement of urine glucose, and none of ten transgenic mice compared to the sera of RIP-LACK or
mice developed diabetes (data not shown). In addition,
RIP-TNFa transgenic mice or negative littermates (Fig-
examination of pancreatic sections from adult RIP-
ure 4). The observed LACK-specific tolerance found in
LACK mice did not reveal any abnormality or evidence
RIP-LACK/RIP-TNFa mice did not appear to be the re-
of insulitis (data not shown).
sult of general immunosuppression, because mice from
the four different groups all mounted comparable re-
sponses when immunized with ovalbumin (Figures 2CPeripheral Tolerance to LACK Occurs in
RIP-LACK/RIP-TNFa Double-Transgenic Mice and 3D).
In contrast to other transgenic strains in which defined
antigens were expressed by islet b cells (Lo et al., 1992; LACK-Reactive CD41 T Cells Are Tolerized
Prior to ImmunizationFoÈ rster et al., 1995), RIP-LACK mice were not tolerant
to LACK. Thus, following immunization with LACK re- Two different mechanisms could explain the impaired
ability of double-transgenic RIP-LACK/RIP-TNFa micecombinant protein in complete Freund's adjuvant (CFA),
lymph node T cells from RIP-LACK mice secreted similar to mount LACK-specific immune responses following
immunization with LACK. One possibility could be thatlevels of interferon-g (IFNg) and interleukin-5 (IL-5) in
response to LACK in vitro when compared to cells from LACK-reactive cells are activated in the draining lymph
Tolerance Due to TNFa Expression in Islets
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Figure 3. The Draining Lymph Nodes of Immunized RIP-LACK/RIP-
TNFa Transgenic Mice Contain Reduced Numbers of LACK-Reac-
tive Th1- and Th2-Like Cells
Lymph node cells from the indicated mice were incubated with an
optimal concentration (25 mM) of LACK or ovalbumin peptide for 72
hr. Live cells were recovered and transferred by serial dilution to
precoated 96-well microtiter plates. After 24 hr, cells were removed
and spots were visualized using biotinylated detecting MAbs before
the number of spots was determined. Data are numbers of (A) IFNg±,
(B) IL-4±, and (C) IL-5±producing cells in response to LACK and (D)
IFNg±producing cells in response to ovalbumin. Data are means 6
SEM for three individual transgenic mice per group.
them from returning to the lymph nodes. Alternatively,
local expression of TNFa and LACK in the pancreas
could alter the phenotype of LACK-reactive cells prior
Figure 2. LACK-Specific Cytokine Responses Are Impaired in RIP-
to immunization, a phenomenon that could then be visu-LACK/RIP-TNFa Transgenic Mice
alized when the mice are immunized with LACK. ToRIP-LACK and RIP-TNFa single-transgenic mice, RIP-LACK/RIP-
determine which of these two hypotheses is correct,TNFa double-transgenic mice, and negative littermates were immu-
we adoptively transferred B cell±depleted spleen cellsnized with 50 mg of LACK or ovalbumin in CFA. Ten days after
immunization, draining lymph node cells were cultured for 72 hr in from single RIP-TNFa or double RIP-LACK/RIP-TNFa
the presence of medium alone or with the indicated concentrations transgenic mice into nude mice. Cells from IE-LACK
of the LACK or ovalbumin peptides. Cytokine production was deter- transgenic mice that were tolerant to LACK as the result
mined by ELISA for (A) IFNg and (B) IL-5 in response to LACK and
of transgenic expression of this protein in the thymus(C) IFNg in response to ovalbumin. There was no detectable IL-4 in
were also used as a control. Nude recipients that re-any of the samples analyzed. Data are means 6 SEM of duplicates
ceived T cells from double RIP-TNFa/RIP-LACK or sin-from three individual mice per group and are representative of four
experiments. gle IE-LACK transgenic mice exhibited an impaired abil-
ity to mount a LACK-specific T cell response following
immunization, in contrast to nude mice that received Tnodes following immunization and then migrate to the
cells from RIP-TNFa single-transgenic mice. Thus,pancreas, where a second encounter with LACK in the
presence of TNFa leads to their tolerization or prevents lymph node cells from mice that received T cells from
Immunity
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Figure 5. LACK-Specific Cytokine Responses Are Impaired in Nude
Mice That Have Been Adoptively Transferred with T Cells from RIP-
LACK/RIP-TNFa Transgenic Mice
Nude mice were injected intraveneously with B cell±depleted spleen
cells from RIP-TNFa or RIP-LACK/RIP-TNFa mice or from IE-LACK
mice, which are tolerant to LACK as the result of the transgenic
expression of LACK in the thymus.One week after adoptive transfer,
mice were immunized with 50 mg of LACK in CFA. Ten days after
immunization, draining lymph node cells were prepared and incu-
bated for 72 hr in the presence of medium aloneor with the indicated
concentrations of LACK peptide. Cytokine production was deter-
mined by ELISA for IFNg as described in the legend to Figure 2.
There was no detectable IL-4 or IL-5 in any of the samples analyzed.
RIP-LACK and TCR-LACK/RIP-TNFa, and single TCR-
LACK transgenic mice were stimulated in vitro with vari-
ous concentrations of LACK peptide in the presence
of syngeneic antigen-presenting cells (APCs) without
Figure 4. LACK-Specific Antibody Responses Are Impaired in RIP- exogeneously added cytokines. We found that CD41 T
LACK/RIP-TNFa Transgenic Mice cells from triple-transgenic mice that expressed both
Mice from the four indicated groups were immunized with 50 mg of LACK and TNFa in the pancreas produced less IL-2 but
LACK in CFA. Ten days after immunization, the presence of serum comparable amounts of IFNg as compared to cells from
IgG2a (A) and IgG1 (B) antibodies from individual mice was deter-
double- or single-transgenic mice (Figures 6A and 6B).mined by ELISA. Data are means 6 SEM for three individual
In contrast, cells from triple-transgenic mice producedtransgenic mice per group.
more IL-4, IL-5, and IL-10 than those from single- or
double-transgenic mice (Figures 6C±6E).
RIP-TNFa mice produced significant amounts of IFNg LACK-specific antibody responses were also moni-
in response to LACK in vitro, while lymph node cells tored in the four groups of TCR transgenic mice by
from RIP-LACK/RIP-TNFa mice failed to produce IFNg enzyme-linked immunosorbent assay (ELISA). In con-
(Figure 5). These data indicate that LACK-reactive T cells trast to LACK-specific IgG1 antibodies, which were not
from RIP-LACK/RIP-TNFa mice are tolerized prior to detectable in any of the mice analyzed, we found high
immunization. levels of LACK-specific IgG2a antibodies in the serum
of TCR-LACK/RIP-LACK transgenic mice (Figure 6F).
Coexpression of LACK and TNFa in Pancreatic b This spontaneous antibody response was not evident
Cells Results in Increased Secretion of Th2-Like in triple TCR transgenic mice that express both LACK
Cytokines by LACK-Specific and TNFa in the pancreas (Figure 6F), a result that is
TCR Transgenic T Cells broadly in agreement with the altered phenotype of
To monitor the effects of TNFa on LACK-specific im- CD41 T cells found in these mice.
mune responses in the absence of immunization, RIP-
LACK/RIP-TNFa double-transgenic mice were crossed Coexpression of TNFa and LACK in the Pancreas
to TCR-LACK transgenic mice in which approximately Leads to a Decrease in the Number of TCR
10% of peripheral CD41 T cells expressa TCR transgene Transgenic T Cells Exhibiting
specific for a class II±restricted LACK peptide (158±173) an Activated Phenotype
(Brown et al., 1997). Purified CD41 cells from triple To determine how TCR transgenic T cells are modified
when they encounter LACK in double-transgenic RIP-TCR-LACK/RIP-LACK/RIP-TNFa, double TCR-LACK/
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Figure 6. CD41 TCR Transgenic T Cells from
RIP-LACK/RIP-TNFa MiceSecrete More Th2-
Like Cytokines but Less IL-2 Than Cells from
Single-Transgenic Mice or Negative Lit-
termates
CD41 T cells were purified from the spleens of
individual TCR-LACK/RIP-LACK, TCR-LACK/
RIP-TNFa, TCR-LACK/RIP-LACK/RIP-TNFa,
and TCR-LACK mice and incubated for 72
hr with syngeneic APCs in the presence of
medium alone or with the indicated concen-
trations of LACK peptide without exoge-
neously added cytokines. Cytokine produc-
tion was determined by ELISA for (A) IFNg,
(B) IL-2, (C) IL-4, (D) IL-5, and (E) IL-10. The
levels of LACK-specific IgG2a in the serum
of these mice was also measured by ELISA
(F). No LACK-specific IgG1 was detected in
these mice (data not shown).
LACK/RIP-TNFa mice, we used flow cytometry to ana- Discussion
lyze and compare the phenotypes of CD41Vb41 T cells
of age-matched and cohoused mice from the four The role that TNFa plays in the development of sponta-
neous diabetes is still a matter of speculation. A numbergroups. Although the total number of CD41Vb41 T cells
was not different among the four groups of mice (data of reports have suggested that transgenic expression
of TNFa in islet b cells favors the development of autore-not shown), we found that the proportion of CD41Vb41
T cells exhibiting an activated large CD44hiCD62Llo phe- active T cells, which then incite a destructive autoim-
mune process. Thus, transgenic mice in which bothnotype was increased in RIP-LACK transgenic mice as
compared to RIP-TNFa transgenic mice or negative lit- TNFa and the costimulatory molecule B7 are expressed
in pancreatic b cells develop spontaneous diabetes,termates (Figure 7). Thus, the expression of LACK in the
pancreas leads to the activation of LACK-reactive TCR whereas mice expressing only the B7 transgene do not
progress from insulitis to diabetes (Guerder et al., 1994).transgenic T cells, a result that is in agreement with the
spontaneous LACK-specific IgG2a antibody response In addition, double-transgenic mice in which both TNFa
and the lymphocytic choriomeningitis virus GP antigenfound in these mice. In mice that expressed both TNFa
and LACK in the pancreas, the proportion of CD41Vb41 are expressed in islet b cells developed diabetes follow-
ing infection with a recombinant GP±vaccinia virus,T cells exhibiting an activated phenotype was reduced,
a phenomenon likely to be linked to the specific toler- while single-transgenic mice expressing only the GP
protein did not (Ohashi et al., 1993). Thus, in both theseance of T cell responses caused by the expression of
TNFa. model systems the local expression of TNFa provides
Immunity
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Figure 7. Flow Cytometric Analysis of TCR Transgenic CD41 T Cells in RIP-LACK/RIP-TNFa Mice
Cell suspensions were prepared from the spleens of the indicated mice and stained with fluorescent antibodies to CD4, Vb4, and CD44 or
CD62L before being processed for flow cytometric analysis. For each marker, typical flow cytometric patterns for (A) forward scatter, (B)
CD44, and (C) CD62L are shown after gating on CD41Vb41cells. Numbers show the percentage of cells within the indicated gates.
an inflammatory environment that allows development of these mice following immunization. The functional
consequence of a lack of T cell help was observed onof autoreactive T cells and subsequent progression to
diabetes. antibody responses: the amounts of LACK-specific IgG1
and IgG2a antibodies were greatly reduced in the dou-In apparent contrast with these results, Grewal et al.
(1996) recently reported that RIP-TNFa mice generated ble-transgenic RIP-LACK/RIP-TNFa mice compared to
mice from the other three groups. What mechanismson a NOD background developed spontaneous insulitis
but failed to progress to a diabetic state, a process that are responsible for this phenomenon? The impaired abil-
ity of the double-transgenic mice to mount a LACK-correlates with a lack of spontaneous responsiveness
to islet antigens that normally occurs in NOD mice. Al- specific T cell response following immunization sug-
gests that LACK-reactive T cells have encountered thethough other mechanisms could be responsible for this
phenomenon, it was proposed that the transgenic ex- antigen, a process that then leads to active tolerization
of these CD41 T cells. Adoptive transfer experimentspression of TNFa in these mice did not allow efficient
costimulation of self-reactive T cells, thus preventing using nude mice were in agreement with this conclusion
and further supported the hypothesis that tolerizationthe spontaneous T cell response to islet antigens that
normally occurs in NOD mice. occured prior to immunization. Thus, local expression
of TNFa in the pancreas does not merely prevent theTo understand better how local expression of TNFa
in islet cells can affect T cell responses to a defined activation of islet specific T cells, as previously sug-
gested (Grewal et al., 1996), but leads to antigen specificislet antigen, we constructed RIP-LACK transgenic mice
in which the expression of the L. major LACK antigen tolerance.
Where do naive LACK-reactive cells encounter thewas restricted to pancreatic b cells. Because the RIP-
LACK mice were fully capable of mounting LACK-spe- antigen for the first time? Although the encounter could
occur in the pancreas, it is unlikely that all cells reactivecific antibody and T cell responses when immunized
with LACK, we were able to determine how local expres- to LACK would traffic to this organ for tolerization. A
second possibility is that the effect is mediated throughsion of TNFa affects LACK-specific immune responses
by crossing RIP-LACK mice to RIP-TNFa mice. In APCs that migrate to the pancreas as a result of
transgenic expression of TNFa, as has been shown inagreement with the report by Grewal et al. (1996), we
found that double-transgenic mice expressing both transgenic mice expressing lymphotoxin in pancreatic b
cells (Kratz et al., 1996). These APCs would then captureLACK and TNFa in pancreatic islets exhibited an im-
paired ability to mount a LACK-specific T cell immune cellular debris from b cells and present them in a tolero-
genic form to the immune system, perhaps after havingresponse. Both Th1 and Th2 compartments were af-
fected, as suggested by the reduced numbers of IFNg±, migrated to the thymus or to the spleen.
The use of TCR-LACK transgenic mice has allowedIL-4± and IL-5±producing cells found in the lymph nodes
Tolerance Due to TNFa Expression in Islets
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us to investigate further the mechanisms by which local Our data may help to explain the apparent dichotomy
in the role of TNFa in the induction of diabetes. Thus,expression of TNFa in islet b cells leads to the develop-
ment of tolerance to a defined pancreatic antigen. How- in models that have been shown to (Ohashi et al., 1993)
or that probably (Guerder et al., 1994) involve the de-ever, our experiments also uncovered further complexi-
ties concerning the effect of TNFa. Surprisingly, we struction of b cells through a CD41-independent pro-
cess, TNFa accelerates the development of the diseasefound that the spleens of TCR transgenic mice that
carried the RIP-LACK but not the RIP-TNFa transgene process. However, we have demonstrated here that
TNFa leads to the tolerance or immune deviation ofcontained more CD41Vb41 T cells exhibiting an acti-
vated phenotype than did the spleens from other TCR CD41 T cells that are required for the diabetogenic pro-
cess in NOD mice. Thus, while TNFa may participate intransgenic mice. This was in agreement with the sponta-
neous LACK-specific IgG2a antibody response found in the development of diabetes once the process of b cell
destruction has begun, our data suggest that the initialthe TCR-LACK/RIP-LACK mice and further suggested
that these T cells were capable of providing help to B role of TNFa may be to prevent the induction of a de-
structive self-reactive response before this occurs. In-cells in vivo following activation. In agreement with a
possible role of TNFa in the down-regulation of T cells deed, such an hypothesis has been suggested but not
demonstrated in studies in which recombinant TNFa orresponses, the proportion of cells expressing an acti-
vated phenotype in RIP-LACK/TCR-LACK mice was re- neutralizing antibodies have been administered to NOD
mice (Yang et al., 1994). Both the arrest of the diabeticduced in mice that also expressed the RIP-TNFa
transgene. Expression of TNFa in the pancreas also process at the insulitis stage in RIP-TNFa/NOD mice
and the fact that RIP-TNFa mice are resistant to strepto-curtailed the spontaneous LACK-specific IgG2a anti-
body response found in the TCR-LACK/RIP-LACK mice. zotocin-induced diabetes (our unpublished data) also
are in agreement with this hypothesis.Although CD41 T cells from TCR-LACK/RIP-LACK/RIP-
TNFa transgenic were partially tolerized, as observed
in their impaired ability to secrete IL-2 in response to Experimental Procedures
antigenic stimulation, they also secreted higher levels
Miceof Th2-like cytokines such as IL-4, IL-5, and IL-10. Thus,
BALB/c and BALB/cByJ-Nude mice were purchased from IFFAlocal expression of TNFa in the islets of the TCR-
Credo and were used at 6±10 weeks of age. Mice were bred intransgenic mice favored the development of LACK-reac-
our core Animal Facility and housed under specific pathogen±free
tive Th2 cells. Because naive T cells do not express TNF conditions. RIP-TNFa (Picarella et al., 1993) and IE-LACK (Julia et
receptors, it is unlikely that TNFa acts directly on these al., 1996) transgenic mice have been described previously. TCR-
LACK mice were produced by microinjection of genomic TCR con-cells. This process maybe explained by TNFa- mediated
structs into (B10.S 3 C57BL/6) F1 fertilized eggs and implantationstimulation of production in vivo of IL-6, a cytokine that
into pseudopregnant foster mothers according to standard proce-recently has been shown to drive Th2 development (Rin-
dures (Hogan et al., 1986) (Reiner et al., unpublished data). Thecon et al., 1997). At this stage, however, we cannot
rearranged a and b chain gene constructs were made from DNA
demonstrate whether TNFa affects T cells directly or via derived from the T helper cell clone 9.1±2 (Scott et al., 1990), which
the induction of other cytokines or effects on antigen is specific for the L. major LACK antigen (Mougneau et al., 1995)
and uses Va8 and Vb4 TCR variable regions. RIP-LACK transgenicpresentation. Future experiments with TNF-receptor
mice were generated by subcloning a truncated LACK cDNA into aknockout mice should allow us to distinguish between
modified RIP-Ea expression vector downstream of the rat insulinthese possibilities. Whatever the mechanism, a similar
gene promoter (RIP) (Guerder et al., 1994) and by injecting thisrole for TNFa in the development of Th2 responses has
construct into (B10.S 3 C57BL/6) F1 fertilized eggs. Three transgene
previously been shown in an adoptive-transfer TCR positive founders were indentified by screening mice by Southern
transgenic model in which TNFa was used as an adju- analysis of tail DNA. Each founder was crossed to BALB/c mice,
and offspring were monitored for LACK expression in pancreaticvant, resulting in the specific production of IgG1 anti-
islets by RT-PCR. For this study, all mice were backcrossed at leastbodies (Pape et al., 1997).
five times on the BALB/c background. Pancreatic sections fromIt is noteworthy that the biased Th2 responses found
RIP-TNFa mice bred to a BALB/c background for five generationsin triple-transgenic mice was not found in double-
showed massive insulitis, as previously reported for the same mice
transgenic RIP-LACK/RIP-TNFa mice following immuni- on a C57BL/6 background (Picarella et al., 1993). Double-transgenic
zation with LACK. A number of mechanisms may ac- mice were generatedby breeding RIP-LACK mice to RIP-TNFamice.
count for this observation. First, the capacity of TNFa Triple-transgenic mice were generated by breeding double RIP-
LACK/RIP-TNFa mice to TCR-LACK mice. Mice were screened forto amplify a Th2 response may depend upon the fre-
RIP-LACK and RIP-TNFa transgenes by PCR analysis of tail DNAquency of antigen-reactive T cells, which is much higher
using the primers LM24 (ATCTGCTTCTCGCCGTCGCT) and LM25in TCR transgenic mice than in mice with an unmanipu-
(GCGTCGGAGATGGACCACAC), or TNF1 (ATTTGAGGGACGCTGT
lated T cell repertoire. Indeed, it has been shown that GGGCTCTT) and TNF2 (TGTGAGGGTCTGGGCCATAGAACTGAT),
the polarization of Th1 and Th2 cells is dramatically respectively. Tail DNA was prepared by proteinase K (Boehringer
affected by alterations in the ratio of antigen to re- Mannheim) digestion, phenol/chloroform (GIBCO±BRL) extraction,
and ethanol precipitation. A 466 bp (LM24 and LM25) PCR productsponding T cells (Hosken et al., 1995). Alternatively,
was amplified from RIP-LACK mice and a 800 bp product fromTCR-LACK transgenic mice exhibit, as do many other
RIP-TNFa mice (TNF1 and TNF2). Mice were screened for the TCRTCR strains, a large proportion of cells exhibiting an
transgene by flow cytometry of peripheral blood cells using the MAb
activated phenotype. Because activated cells, in con- KT4.1.
trast to naive cells, express TNFa receptors, it is possi-
ble that TNFa exerts a direct cytotoxic effect on these Reagents and Antibodies
cells, possibly by inducing the preferential cell death of LACK recombinant protein was produced in Escherichia coli and
purified as described (Mougneau et al., 1995). LACK (amino acidsTh1-like cells.
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158±173, FSPSLEHPIVVSGSWD) and OVA peptides (amino acids Adoptive Transfer to Nude Mice
Spleen cells from RIP-TNFa, RIP-LACK/RIP-TNFa or IE-LACK mice323±338, ISQAVHAAHAEINEAG) werepurchased from Chiron Mimo-
topes. The following MAbs were used for cell purification or analysis: were depleted of sIg1 B cells by panning using sheep anti-mouse
Ig serum (Cappel Laboratories). After washing, cells were injectedGK1.5, anti-CD4 (Dialynas et al., 1983); Mel-14, anti-CD62L (Phar-
Mingen, San Diego, CA); 7D4, anti-IL-2 receptor a (PharMingen); into the tail vein of nude recipients.
IM7, anti-CD44 (PharMingen); KT4.1, anti-Vb4 (Tomonari et al.,
1990); 11B11, anti-IL-4 (Ohara and Paul, 1985); R46A2, anti-IFNg; Cytokine Production by CD41 TCR Transgenic T Cells
and anti-mouse IgG2a and IgG1 (PharMingen). Recombinant mouse CD41 T cells from the spleen of TCR-LACK, TCR-LACK/RIP-LACK,
IL-2 and IL-5 were purchased from Genzyme (Cambridge, MA). Re- TCR-LACK/RIP-TNFa, and TCR-LACK/RIP-LACK/RIP-TNFa trans-
combinant IFNg was a kind gift from B. Stockinger (National Institute genic mice were purified from individual mice by positive selection.
for Medical Research, London, UK), and recombinant IL-4 and IL- In brief, spleen cells were incubated on ice with fluorescein isothio-
10 were generously provided by F. Y. Liew (University of Glasgow, cyanate (FITC)±conjugated anti-CD4 followed by anti-FITC mi-
Glasgow, UK). crobeads (Miltenyi Biotech) before selection using a magnetic cell
sorter according to the manufacturer's intructions. All samples were
at least 98% pure as assessed by flow cytometry after two serialRNA Analysis
passages through the columns. Purified CD41 T cells (1±2 3 105)RNA from different tissues was extracted by acid guanidinium-thio-
were incubated in round-bottom 96-well tissue culture plates withcyanate (Chomczynski and Sacchi, 1987), treated with DNAse I
mitomycin C±treated spleen cells as APCs and various concentra-(Boehringer Manheim), reverse transcribed (GIBCO±BRL) intocDNA,
tions of LACK peptide. After 72 hr, supernatants were harvestedand then amplified by 35 cycles of PCR using the primers LM4
and examined for the presence of cytokines.(GGAATTCATTGCGGAGCTGACG) and LM16 (GGGTTCGAATTACT
CGGCGTCGGAGATT), which resulted in a 150 bp product. Samples
Flow Cytometry Analysiswere analyzed by electrophoresis through a 2% agarose gel. HPRT
Single-cell suspensions were prepared from the spleens of(hypoxanthine phosphoribosyl transferase) primers were used for
transgenic mice, depleted of erythrocytes by hypotonic lysis, andRNA from all tissues as a control for the efficiency of cDNA synthesis.
stained at 48C in phosphate-buffered saline containing 5% FCS.
Fluorescein- and phycoerythrin-conjugated MAbs specific for
Immunization mouse CD4, Vb4, CD44, and CD62L were used for triple staining.
Mice were immunized in each hind footpad with 50 mg of LACK or Viable cells (106 cells per sample), gated by exclusion of propidium
ovalbumin (Sigma) in CFA (1:1) (Sigma), and draining lymph node iodide±positive cells, were analyzed on a FACScan flow cytometer
cells were harvested 10 days later. (Becton Dickinson).
Tissue Culture Medium Statistical Analysis
Dulbecco's modified Eagle's medium (DMEM) supplemented with Significant differences between groups were evaluated using a two-
10% heat-inactivated fetal calf serum (FCS), penicillin (100 U/ml), tailed Student's test (p , 0.05).
streptomycin (100 mg/ml), 1 mM sodium pyruvate, L-glutamine (2
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